Market Research Logo

Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

About Hypertrophic Cardiomyopathy Therapeutics

HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to various organs difficult. Therefore, the heart must induce more pressure to pump blood to various vital organs.

Technavio’s analysts forecast the global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypertrophic cardiomyopathy therapeutics market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of operating in this market.

Key vendors
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
Other prominent vendors
  • Gilead Sciences
  • Novartis
  • Teva Pharmaceutical Industries
Market driver
  • Adoption of sedentary lifestyle.
  • For a full, detailed list, view our report
Market challenge
  • Technological advances in devices.
  • For a full, detailed list, view our report
Market trend
  • Development of translational bioinformatics (TBI).
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are in this market space?
  • What are the market opportunities and threats faced by the key vendors??
  • What are the strengths and weaknesses of the key vendors??

Press Release

Technavio Announces the Publication of its Research Report – Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021

Technavio recognizes the following companies as the key players in the global hypertrophic cardiomyopathy therapeutics market: AstraZeneca, Merck, Pfizer, and Sanofi

Other Prominent Vendors in the market are: Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from Technavio’s team said: “One trend in market is development of TBI. HCM is a complex genetic disorder, which requires an integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches that can integrate and analyze these heterogeneous features are being developed in order to enhance the clinical guidelines for treatment and prevention of HCM and are named as TBI. TBI is a computational approach, which focuses on the integration and analysis of bioinformatics, biostatics, statistical genetics, and clinical informatics. It acts as a data-storage source, which not only performs data integration but also improves data representation. This will be done by using tools such as ontology and controlled vocabulary, as they provide a standard way for representation of data. These vocabulary sources are references that are accepted by specific user community like Gene Ontology and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT).”

According to the report, one driver in market is increasing cases of HF. HCM is an extended form of a diastolic HF when the heart fails to perform its functions normally. The diastolic HF occurs when the lower left chamber or the LV is not filled properly with blood during the diastolic phase. Therefore, the amount of pumped blood is less than the normal. Similarly, in HCM, the increasing myocardium size results in smaller LV cavity size accompanied by impairment of blood flow. This leads to the common symptoms of both HCM and HF such as dyspnoea, angina, palpitations, syncope, and presyncope. Hence, the drug development for relieving the symptoms of HF benefits the global HCM therapeutics market as well. As per the CDC, more than five million people are living with HF in the US, and about half of the affected population succumb within five years of diagnosis. However, the deaths due to HF have significantly declined in the past few years due to improved therapies to treat the disease. However, the risk of developing HF continues to rise with the increasing population. This risk-factor has further triggered R&D for newer drugs, which can be repurposed for the diagnosis and treatment of HCM. The traditional HCM drug market has a long history of repurposed drugs for its prevention and cure. There are many drugs belonging to drug classes such as beta-adrenergic blockers, calcium channel blockers, and antiarrhythmic, which were originally developed for the treatment and prevention of HF and are now being employed in the treatment of HCM.

Further, the report states that one challenge in market is expensive serial screenings. Individuals with HCM may be asymptomatic or may complain of mild chest pain; CHF symptoms; or syncope, which is the temporary loss of consciousness due to fall in BP. The morphologic diagnosis is characterized by the presence of hypertrophied myocardium and non-dilated LV in the absence of other cardiac diseases that are capable of causing myocardium hypertrophy of more than 15 mm in an adult patient or equivalent to relative body surface area in children. The serial screening for evaluation of HCM includes two-dimensional echocardiography ($1,500), 24-hour ambulatory (Holter) electrocardiographic monitoring, 12-lead ECG, CMR, and TTE ($2,000) and evaluation by a cardiologist at an experienced center. These tests are not only time consuming but also very expensive and may pose a financial burden on an individual's family, thereby increasing anxiety and stress for the family.

Companies Mentioned

AstraZeneca, Merck, Pfizer, Sanofi, Gilead Sciences, Novartis, and Teva Pharmaceutical Industries.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • Disease overview
    • Table Types of HCM
    • Table Treatment for HCM
  • Key clinical trials
    • Table Snapshot of HCM therapeutics pipeline 2016
    • Table Pipeline analysis for HCM therapeutics market
  • Market dynamics
    • Table Mutation
    • Table Identification of pathogenicity in genes by genetic testing
  • Market landscape
    • Market overview
      • Table Global HCM therapeutics market snapshot
      • Table Global HCM therapeutics market 2016-2021 ($ millions)
      • Table Opportunity analysis in global HCM therapeutics market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug-class
    • Table Market segmentation based on drug class
    • Global calcium channel blockers market
      • Table Global calcium channel blockers market 2016-2021 ($ millions)
    • Global beta-adrenergic blockers market
      • Table Global beta-adrenergic blockers market 2016-2021 ($ millions)
    • Global antiarrhythmic market
      • Table Global antiarrhythmic market 2016-2021 ($ millions)
    • Global anticoagulants market
      • Table Global anticoagulants market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Global HCM therapeutics market by geography 2016 and 2021
    • Table Global HCM therapeutics market by geography 2016-2021 ($ millions)
    • HCM therapeutics market in Americas
      • Table Market scenario in Americas
      • Table HCM therapeutics market in Americas 2016-2021 ($ millions)
    • HCM therapeutics market in EMEA
      • Table Market scenario in EMEA
      • Table HCM therapeutics market in EMEA 2016-2021 ($ millions)
    • HCM therapeutics market in APAC
      • Table Market scenario in APAC
      • Table HCM therapeutics market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Prevalence of obesity among US adults 2015
    • Market challenges
    • Impact of drivers and challenges on key customer segments (hospitals and pharmacies)
      • Table Impact of drivers and challenges
  • Market trends
    • Increasing availability of genetic tests
      • Table Group of HCM individuals based on genetic tests
    • Development of TBI
    • Advent of genomic medicine
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global HCM therapeutics market 2016
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Key highlights
      • Table AstraZeneca: Strength assessment
      • Table AstraZeneca: Strategy assessment
      • Table AstraZeneca: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report